Patents by Inventor Marcus E. Carr

Marcus E. Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11167058
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: November 9, 2021
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Patent number: 9821084
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: November 21, 2017
    Assignee: Virginia Commonwealth University
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Publication number: 20130310779
    Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.
    Type: Application
    Filed: July 26, 2013
    Publication date: November 21, 2013
    Applicant: Virginia Commonwealth University
    Inventors: Gary Wnek, Marcus E. Carr, JR., Gary Bowlin, Kelman I. Cohen, Kevin R. Ward, Wayne Barbee, Rao Ivatury
  • Patent number: 8586345
    Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: November 19, 2013
    Assignee: Virginia Commonwealth University Intellectual Property Foundation
    Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
  • Patent number: 8497408
    Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: July 30, 2013
    Assignee: Virginia Commonwealth University
    Inventors: Gary Wnek, Marcus E. Carr, Jr., Gary Bowlin, Kelman I. Cohen, Kevin R. Ward, Wayne Barbee, Rao Ivatury
  • Publication number: 20120219612
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Application
    Filed: May 10, 2012
    Publication date: August 30, 2012
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Publication number: 20110288026
    Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.
    Type: Application
    Filed: March 21, 2011
    Publication date: November 24, 2011
    Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
  • Publication number: 20100310658
    Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs.
    Type: Application
    Filed: June 8, 2010
    Publication date: December 9, 2010
    Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, JR.
  • Publication number: 20100291058
    Abstract: The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants.
    Type: Application
    Filed: April 12, 2010
    Publication date: November 18, 2010
    Applicants: Virginia Commonwealth University, Nanomatrix, Inc.
    Inventors: Gary L. Bowlin, David G. Simpson, Gary E. Wnek, Marcus E. Carr, JR., Peter J. Stevens, Gary Cadd, I. Kelman Cohen
  • Publication number: 20100292624
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: November 18, 2010
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Patent number: 7759082
    Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: July 20, 2010
    Assignee: Virginia Commonwealth University Intellectual Property Foundation
    Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, Jr.
  • Patent number: 7615373
    Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: November 10, 2009
    Assignees: Virginia Commonwealth University Intellectual Property Foundation, Organogenesis, Inc.
    Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
  • Publication number: 20090155342
    Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.
    Type: Application
    Filed: February 15, 2006
    Publication date: June 18, 2009
    Applicant: Virginia Commonwealth University
    Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
  • Patent number: 7468067
    Abstract: Provided is a tourniquet having two opposing and pivotally movable plates. The plates comprise a clamp that pinches an elastomeric cord. The plates are pivotally biased together by a spring. The cord is attached to a back end of the clamp. A free end of the cord is squeezed by the plates such that a loop of cord is provided. The cord can be pulled from the clamp to reduce the size of the loop. The clamp comprises a safety lock that prevents movement of the plates and slipping of the cord. The safety lock can comprise a button disposed between the plates in the back end of the clamp, preventing the plates from moving together in the back portion, and therefore from moving apart in a front portion that grips the cord. Also, the tourniquet clamp can comprise a dual-sided press connector mechanism for fast release of tourniquet tension.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: December 23, 2008
    Assignees: Virginia Commonwealth University, Biotrack, LLC
    Inventors: Mark Licata, Kevin R. Ward, Marcus E. Carr, Jr.
  • Patent number: 7192726
    Abstract: Platelet contractile force and/or clot elastic modulus measurements are used to identify patients at risk for atherosclerosis or for bleeding during surgical procedures or other applications. Measurements which are elevated are indicative of atherosclerosis, and measurements which are reduced are indicative of a bleeding risk.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: March 20, 2007
    Assignee: Hemodyne, Inc.
    Inventors: Marcus E. Carr, Jr., Ashok Krischnaswami, Erika Martin
  • Publication number: 20040229333
    Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.
    Type: Application
    Filed: January 26, 2004
    Publication date: November 18, 2004
    Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr
  • Patent number: 6787357
    Abstract: The invention is directed to use of fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or “organ-like” tissue. A preferred embodiment is a plasma-derived fibrin matrix containing cells.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: September 7, 2004
    Assignee: Virginia Commonwealth University
    Inventors: Gary L. Bowlin, Gary Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, Helen Fillmore
  • Publication number: 20040037813
    Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.
    Type: Application
    Filed: May 28, 2003
    Publication date: February 26, 2004
    Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
  • Publication number: 20040013715
    Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.
    Type: Application
    Filed: August 13, 2003
    Publication date: January 22, 2004
    Inventors: Gary Wnek, Marcus E Carr, Gary Bowlin, Kelman I Cohen, Kevin R Ward, Wayne Barbee, Rao Ivatury
  • Patent number: 6573104
    Abstract: Blood clot analysis instrumentation used to evaluate platelet function and clot structure by monitoring force development during clot retraction or upon application of a known amount of force can have a calibration check automatically performed by using a top member with a known amount of mass which is detachable from the instrumentation, and preferably is a disposable component. The calibration check is performed by monitoring force or displacement on a holding member with and without the top member attached. If the difference measured is within a preferred tolerance range, then the instrumentation can be deemed to be within the specifications deemed best suited for the instrument. The top member may also be modified to allow for mixing reagents with the clot, thereby avoiding the need to pre-mix blood with reagents before measurement.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: June 3, 2003
    Assignee: Hemodyne, Incorporated
    Inventors: Marcus E. Carr, Jr., Mark Licata